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Background: Cryptorchidism is the most frequent congenital disorder in male children; however the genetic
causes of cryptorchidism remain poorly investigated. Comparative integratomics combined with systems biology
approach was employed to elucidate genetic factors and molecular pathways underlying testis descent.
Methods: Literature mining was performed to collect genomic loci associated with cryptorchidism in seven
mammalian species. Information regarding the collected candidate genes was stored in MySQL relational database.
Genomic view of the loci was presented using Flash GViewer web tool (http://gmod.org/wiki/Flashgviewer/). DAVID
Bioinformatics Resources 6.7 was used for pathway enrichment analysis. Cytoscape plug-in PiNGO 1.11 was
employed for protein-network-based prediction of novel candidate genes. Relevant protein-protein interactions
were confirmed and visualized using the STRING database (version 9.0).
Results: The developed cryptorchidism gene atlas includes 217 candidate loci (genes, regions involved in
chromosomal mutations, and copy number variations) identified at the genomic, transcriptomic, and proteomic
level. Human orthologs of the collected candidate loci were presented using a genomic map viewer. The
cryptorchidism gene atlas is freely available online: http://www.integratomics-time.com/cryptorchidism/. Pathway
analysis suggested the presence of twelve enriched pathways associated with the list of 179 literature-derived
candidate genes. Additionally, a list of 43 network-predicted novel candidate genes was significantly associated
with four enriched pathways. Joint pathway analysis of the collected and predicted candidate genes revealed the
pivotal importance of the muscle-contraction pathway in cryptorchidism and evidence for genomic associations
with cardiomyopathy pathways in RASopathies.
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Conclusions: The developed gene atlas represents an important resource for the scientific community researching
genetics of cryptorchidism. The collected data will further facilitate development of novel genetic markers and
could be of interest for functional studies in animals and human. The proposed network-based systems biology
approach elucidates molecular mechanisms underlying co-presence of cryptorchidism and cardiomyopathy in
RASopathies. Such approach could also aid in molecular explanation of co-presence of diverse and apparently
unrelated clinical manifestations in other syndromes.
Keywords: Cryptorchidism, Muscle-contraction pathway, Cardiomyopathy, Comparative integratomics,
Protein-protein interactions, Systems biology, Undescended testes, RASopathyBackground
Cryptorchidism (CO) is the most frequent congenital
disorder in male children (2-4% of full-term male births)
and is defined as incomplete descent of one (unilateral)
or both (bilateral) testes and associated structures.
Cryptorchidism has a potential effect on health; defects
in testes descent usually cause impaired spermatogen-
esis, resulting in reduced fertility and increased rates of
testicular neoplasia, and testicular torsion (reviewed in
[1]). Cryptorchidism is common in human, pigs, and
companion animals (2–12%) but relatively rare in cattle,
and sheep (≤ 1%) [2].
Testicular descent is a complex series of events which
requires concerted action of hormones, constitutive
mechanisms, and the nervous system. In most species,
including human, the complete descent of testes usually
occurs prenatally, while in some (e.g. dogs), postnatally.
Beside environmental factors like endocrine disruptors,
CO is at least in part determined by genetic causes
(chromosome or gene mutations), and is often a common
feature of different syndromes. For example, Klinefelter
syndrome and mutations in INSL3 gene have already been
recognized as a cause of CO in some cases [3].
The comparative knowledge attained through study of
animal models has been of great importance in
understanding complex disease etiology, suggesting sev-
eral candidate genes involved also in the pathogenesis of
human diseases [4]. Therefore, the use of comparative
genomics approach, integrating and cross-filtering the
available knowledge from different species seems highly
justified. Different animal models for CO exist; for ex-
ample natural mutants or transgenic mice, rat, rabbit,
dog, pig and rhesus monkeys are used to elucidate the
role of different factors involved in CO [5]. Based on
mouse knock-out models from Mouse Genome Inform-
atics (MGI) database, several genes appear as possible
candidates (AR, HOX genes, INSL3, RXFP2, and WT1).
Additionally, the technological progress in the last years
enabled the use of high-throughput omics-information,
at coding (DNA), expression (RNA), and proteomic
level. This technological revolution creates a vast
amount of data, which increases the need for applicationof bioinformatics tools that are able to connect omics
data with phenotype and enable search for overlapping
pathogenetic mechanisms in different genetic diseases
[6]. However, this existing technology hasn’t been signifi-
cantly employed in human CO research on a genome
and transcriptome-wide scale; to date only one genome-
wide expression study has been performed in rat [7].
Integratomics represents a novel trend in the omics-
research and is based on the integration of diverse
omics-data (genomic, transcriptomic, proteomic, etc.),
regardless of the study approach or species [8-10]. High
genetic homology between mammals and the availability
of well annotated genomes from different species allows
the assembled data to be presented in a form of a com-
parative genomic view, displaying candidate genes as a
single species orthologs.
Information extracted from diverse and methodologic-
ally focused studies are often fragmented and controver-
sial. To overcome this problem we integrated the collected
data, using a holistic (map-driven) approach, and developed
freely available interactive genomic visualization tool. Such
map-based approach allows identification and prioritization
of candidate genes [11] based on a number of literature
sources (references), genomic position, and pathway ana-
lyses, employing all currently available knowledge in differ-
ent species. However, extrapolating the gained knowledge
from one species to another is often difficult due to differ-
ent anatomical and physiological characteristics, which
should be considered when comparing pathology of the
disease in different species.
To identify genetic factors potentially involved in CO
pathogenesis in human we 1) applied comparative
integratomics approach and assembled the database of all
CO-associated genomic loci reported in the literature, re-
gardless of the study approach and species, 2) presented the
loci on a genomic map as human orthologs, and 3)
prioritized the collected data using systems biology ap-
proach. The collected candidate genes were classified in
corresponding biological pathways and the most significant
CO-enriched pathways were proposed. Such classification
of candidate genes allowed us to prioritize biological
pathways (characterized by genes involved in the
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pathways (for example muscle contraction mechanisms)
that may also play a role in the pathogenesis of other clin-
ical features distinctive for different syndromes often con-
current with CO. In order to additionally illuminate the
CO-associated pathways we performed a network-based
protein-protein interaction analysis, which resulted in pre-
diction of 43 additional CO candidate genes.
Methods
In search for CO associated candidate loci seven differ-
ent research approaches were considered: (i) chromo-
somal abnormalities associated with CO, (ii) copy
number variations, (iii) clinical syndromes with known
genetic mutations that feature CO, (iv) transgenes and
knock-outs that result in CO associated phenotypes, (v)
association studies/mutation screening that show associ-
ation between sequence variation/mutation screening
and CO, (vi) expression patterns associated with CO,
and (vii) candidates associated with CO at proteomic
level.
Data mining
We reviewed the literature published up to 9/2012
searching for the relevant publications through PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) and Web of Sci-
ence (http://isiknowledge.com) using key phrases: genet-
ics, gene candidates, cryptorchidism, testicular descent,
undescended testes, male infertility, QTL, microarray,
association, microRNA, non-coding RNA, epigenetic,
reproduction, and assisted reproduction. CO-associated
candidate genes from different sources and species were
retrieved from the literature search. Human clinical
syndromes that may cause or feature CO were retrieved
from Online Mendelian Inheritance in Man (OMIM) data-
base (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim)
and Disease database (http://www.diseasesdatabase.com/).
The data for CO-related experiments on mouse models
were retrieved from the Mouse Genome Informatics (MGI)
database (http://www.informatics.jax.org/). Human orthologs
for the CO associated genes were extracted from the MGI
database, which contains information about mammalian
ortholog genes for different species. Overlap analysis of the
CO candidate genes with genomic regions involved in
chromosome mutations was performed using data retrieved
from Ensembl via BioMart data mining tool.
Database implementation
CO-associated candidate genes database is a web re-
source, which provides integrated and curated informa-
tion on molecular components involved in the
pathogenesis of CO. Information regarding collected CO-
associated candidate genes has been stored in relational
MySQL database, which is publicly available for search,data entry and update at http://www.integratomics-time.
com/cryptorchidism/. Search interface enables users to
find specific CO-associated candidate genes based on
the number of criteria. Online data entry interface
enables users to update or submit new CO-associated
candidate genes.Genomic view of the CO associated loci
Overview of the chromosomal locations of CO
associated loci is graphically represented in genomic
view, as previously described [12]. It is possible to
visualize the literature-collected and network-predicted
CO genes on the same genomic view or separately. Gen-
omic view is visible through the web-based interactive
visualization tool Flash GViewer (http://gmod.org/wiki/
Flashgviewer/), which was developed by the GMOD
project.Pathway and network analysis
In the first pathway analysis we considered human
orthologs of the literature-collected candidate genes
(179 genes). DAVID Bioinformatics Resources 6.7 [13]
was employed for the enrichment (overrepresentation)
analysis. The background for the analysis was defined
using the 179 candidate genes plus their first neighbours
(5018 proteins) selected in the human protein-protein
interaction network (PPIN). The result of the enrich-
ment analysis was obtained using Bonferroni multiple
test correction and a p-value significant threshold of
0.01. The human PPIN was obtained by fusion of the
following human networks: IRefIndex [14], Chuang
et al. article [15], Ravasi et al. article [16], Consensus-
PathDB [17].
A new cohort of 43 candidate genes was predicted
using PiNGO 1.11 [18]. PiNGO is a tool designed to find
candidate genes in biological networks and it is freely
provided as a plug-in for Cytoscape 2.8 [19], which is an
open source software platform for visualizing and inte-
grating molecular interaction networks. PiNGO predicts
the categorization of a candidate gene based on the
annotations of its neighbors, using enrichment statistics.
In our analysis we quested which first-neighbour-genes
significantly interact with the original cohort of 179
literature-collected genes in the human PPIN. We
adopted: hypergeometric statistical test, Bonferroni mul-
tiple testing correction and p-value significant threshold
of 0.01. The cohort of 43 network-predicted genes
resulted strongly significant (Bonferroni p-value < 0.0095)
for being new candidate genes.
In order to evaluate the importance of this new cohort
of 43 candidate genes we performed the pathway ana-
lysis according to the procedure already described for
the 179 literature-collected candidate genes.
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between the 179 literature-collected and 43 network-
predicted genes, we repeated the pathway analysis in
DAVID (using the same procedure previously described)
considering the 222 (179 + 43) candidate genes. The
background for the analysis was defined using the 222
candidate genes plus their first neighbours in the human
PPIN. In addition, we visualized the protein-protein
interactions occurring between the genes present in at
least two pathways using the STRING database (version
9.0) [20] and selecting only interactions with high confi-
dence score.Genetic variability of candidate genes
Genetic variability for the most promising CO candi-
date genes was extracted from the Ensembl database
(http://www.ensembl.org/). Probably damaging genetic
variations were predicted by PolyPhen-2, version 2.1.0,
provided by Ensembl database. Putative polymorphic
miRNA target sites in candidate genes were obtained
from Patrocles database (http://www.patrocles.org/) [21].Figure 1 Workflow of the study.Results and discussion
Extensive literature mining was performed resulting in
217 collected candidate loci (chromosome regions and
genes) reported to be involved in CO in human or/and
animals. The generated database served as the founda-
tion for the development of freely available interactive
genomics viewer designed to integrate multi-species data
from various research approaches. Enriched biological
pathways and 43 additional CO candidate genes were
suggested, based on protein-protein interaction network
(PPIN) analysis. The workflow of the study is presented
in the Figure 1.Collection of the cryptorchidism associated loci from the
literature
The collected data incorporates genomic loci associated
with cryptorchidism by seven different types of research
approaches (chromosomal mutations, copy number
variations, clinical syndromes, transgenes and knock-outs,
association studies/mutation screening, transcriptomic/ex-
pression studies, and proteomic studies). The collected
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tle, horse, sheep, dog, rat, and mouse) (Table 1). The
collected CO data is available in Additional file 1: Table
S1, Additional file 2: Table S2, Additional file 3: Table S3,
Additional file 4: Table S4 and Additional file 5: Table S5
and include physical locations of the candidate loci in
human and species of origin.Chromosomal aberrations and copy number variations
We reviewed studies reporting 32 different chromosomal
mutations including numerical and structural aberrations
associated with cryptorchidism [22-33]. Additionally, two de
novo copy number variations (CNVs) - microduplications
were found to be associated with CO using array-based
comparative genomic hybridization (aCGH) [34]. The
collected data is available in Additional file 1: Table S1.Clinical syndromes
Studies of complex disease traits can be facilitated by
analysis of the molecular pathways represented by genes
responsible for monogenic syndromes that also exhibit
these traits [7,35]. There are over 200 different human
syndromes with known molecular basis in OMIM data-
base that feature “cryptorchidism” or “undescended
testis” as a possible feature in their clinical synopsis.
Since cryptorchidism phenotype prevalence is low in
some syndromes, and could only occur coincidentally, it
is difficult to justify association of syndrome causative
genes with a particular phenotype.
To collect CO candidate genes (Additional file 2: Table S2)
we obtained list of syndromes from the literature [4,36,37],
OMIM and Diseases database (“may be caused or feature”)
and then further examined phenotype-gene relationships
and clinical features for each of the syndromes. OnlyTable 1 The summary of CO associated candidate loci
Locus type / study approach Number of loci
DNA level
Chromosomal aberrations 32
Copy number variants (CNVs) 2
Clinical syndromes 42





Injection of exogenous protein 1
Total 217*
* Unique loci (individual locus/gene reported by multiple studies was counted
only once).syndromes where cryptorchidism is present as a regular fea-
ture, described in multiple clinical cases, and where gene(s)
causing the syndrome is/are known were included.
Transgenes and knock-outs
From the Mouse Genome Informatics (MGI) database and
the literature [38-42] we retrieved 39 mouse and one rat
KO and transgenic experiments that result in phenotypes
associated with CO (Additional file 3: Table S3).
Association studies/mutation screening
Nine genes (AR, BMP7, ESR1, HOXA10, INSL3, KISS1R,
NR5A1, RXFP2, and TGFBR3) in human [43-59], INSL3
in sheep [60] and dog [61], and COL2A1 in dog [62]
showed positive association between sequence poly-
morphisms/mutations and CO susceptibility (Additional
file 4: Table S4). In the case of androgen receptor (AR)
gene Ferlin et al. [45] found no difference between the
numbers of CAG and GGC repeats, resulting in variable
lengths of PolyGln/PolyGly in the AR gene and crypt-
orchidism; however, it has been proposed that a particular
combination of the PolyGln/PolyGly polymorphisms may
be linked to CO. In some cases opposing results have been
found; for example, no association between the sequence
polymorphisms and CO have been found for the genes
ESR1 [63-65], INSL3 [66-68], HOXA10 [69], and RXFP2
[70]. The LHCGR has been excluded as a CO candidate
gene in an association study in men [71], although KO of
this gene in mice showed cryptorchid phenotype (MGI)
and is causative gene of Leydig cell hypoplasia-a syndrome
that features CO as one of the clinical signs (OMIM). In
addition, Y chromosome microdeletions have been found
to be present in patients with CO, but are not likely to be
a common etiological cause of CO [72-74].
Expression patterns
There are several studies comparing expression profiles
in testes between cryptorchid and normal males investi-
gating the resulting effects of but not causes for develop-
ment of CO (e.g. [75,76]). To our knowledge, there is
only one microarray study that analyzed transcript
profiles in gubernaculum during normal and abnormal
testicular descent and reported 3589 differentially
expressed genes between inherited cryptorchydism orl
rats and a control group [7]. We included a subset of
112 promising candidate genes to our candidate gene list
that were selected by the authors of the study based on
expression levels, inclusion in specific pathways of inter-
est and/or previous reports showing association with
cryptorchidism (Additional file 5: Table S5).
Protein level
Hutson et al. (1998) [77] investigated the effect of ex-
ogenous calcitonin gene-related peptide (CGRP) in
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also known as calcitonin gene-related peptide B
(CALCB), stimulated migration of inguinal testes that
had been arrested in the line of descent, while ectopic
testes did not respond. The results support the role for
this protein in testicular descent. However, mutation
screening performed by Zuccarello et al. (2004) [78]
failed to confirm CGRP (in human also known as
CALCA) pathway genes as a major players in human
sporadic CO.
Development of the CO database and genomic viewer
The CO-associated loci, obtained by comparative
integratomics approach, were assembled into a freelyFigure 2 Genomic view of the cryptorchidism candidate genes. A. Gen
(blue) CO associated candidate loci presented as human orthologs. The vie
mouse transgenic and knock-out experiments, chromosomal abnormalities
associated with CO, and genes associated with CO on proteomic level. Loc
B. Enlargement of the chromosome 9.accessible database available at http://www.integratomics-
time.com/cryptorchidism/. The curated database is open
for public data entry. Researchers are invited to submit
new cryptorchidism candidate genes from their research
or other publications by filling data entry form on our
web site. The collected loci from human and animal spe-
cies were presented as genomic view for human orthologs
(in a form of a human genomic view) (Figure 2).
Some candidate genes have been associated with CO
by multiple independent literature reports in multiple
species. For example, twenty genes (AMH, AMHR2, AR,
ARID5B, BMP7, EPHA4, ESR1, FGFR2, HOXA10, HRAS,
INSL3, LHCGR, MAP2K1, MSX1, NR5A1, RXFP2, SOS1,
TNNI2, TNNT3, and WT1) have been associated withomic view of the literature-collected (red) and network-predicted
w includes syndromes with known genetic mutations that feature CO,
, genes tested for association with CO, genes with expression patterns
i are placed at approximate positions on chromosome map.
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study approaches (Table 2). These genes are denoted in
bold in the online database (http://www.integratomics-
time.com/cryptorchidism/candidate_genes/).
The CO associated loci mapped to all human
chromosomes, except HSA21. Genomic distribution of the
selected loci revealed several overlapping areas between the
candidate loci. Overlaps between structural chromosomal
mutations and candidate genes can be observed in Figure 2
or by using interactive genomic view available on the web-
site (http://www.integratomics-time.com/cryptorchidism/
genomic_view/). Genomic regions involved in chromosome
mutations on chromosomes 2, 4, 8, 9, 11, and X [22-33]
overlapped with 13 literature-collected candidate genes:
CAPG, MSX1, E2F5, PTCH1, BICD2, RPS6, FGFR2, HRAS,
PAX6, WT1, TNNI2, TNNT3, FLNA, and MECP2. For in-
stance, a breakpoint on 11p15.5 overlapped with three CO
candidate genes: HRAS, TNNI2, and TNNT3. Additionally,
in some cases two regions involved in chromosome
mutations overlapped; duplication on position 4p over-
lapped with MSX1 gene and the region involved in
chromosomal translocation on position 4p12. Interestingly,
three network-predicted candidate genes, FHL2, TMOD1
and MYBPC3, also overlapped with genomic regions


























WT1 human mousePathway identification and network-based data mining
discovery
Pathway analysis of the cryptorchidism associated
candidate genes
We performed pathway analysis of the 179 literature-
collected CO-candidate genes (refer to Methods). This
pathway enrichment analysis, conducted by applying
very stringent criteria (Bonferroni multiple test correc-
tion and p-value significant threshold of 0.01), yielded
the presence of twelve significant pathways associated
with the list of our CO candidate genes in human
(Table 3). The literature-collected candidate genes
involved in multiple (at least four) pathways are
presented in Additional file 6: Table S6 and marked with
an asterisk in the online database.
The presence of pathways related to “cytoskeleton”,
“muscle development”, “muscle contraction”, “focal ad-
hesion”, and “insulin signaling” was previously reported
in rat [7]. In addition to these pathways, our analysis
showed new pathways: “cardiomyopathy” (hypertrophic
and dilated),“RAS signaling”, “signaling by PDGF”, “sig-
naling by EGFR”, “role of MAL in Rho-mediated activa-
tion of SRF”, “IGF-1 signaling pathway”, and “integrin
signaling”. The results represent a valid example of





















Table 3 Pathway analysis of the literature-collected and network-predicted candidate genes, respectively
Database Pathway Bonferonni
p-value
Candidate genes involved in the pathway
Literature-collected candidate genes
KEGG Regulation of actin
cytoskeleton
4.70E-06 ACTB, BRAF, CDC42, CFL1, CHRM3, EZR, FGD1, FGF9, FGFR1, FGFR2, HRAS, ITGB1, KRAS,
MAP2K1, MAP2K2, MYL2, MYL9, PDGFA, PFN1, PPP1CA, PPP1CB, PXN, RAC1, RAF1, RHOA,
RRAS, SOS1
REACTOME Muscle contraction 5.39E-06 DES, MYH3, MYL2, MYL3, TNNI2, TNNT2, TNNT3, TPM1, TPM3, TPM4, TTN
KEGG Focal adhesion 1.05E-05 ACTB, BRAF, CCND1, CDC42, COL1A2, COL2A1, COL5A1, FLNA, GRB2, GSK3B, HRAS, IGF1, ILK,
ITGB1, MAP2K1, MYL2, MYL9, PDGFA, PPP1CA, PPP1CB, PXN, RAC1, RAF1, RHOA, SOS1, THBS4
REACTOME Signaling by PDGF 3.61E-5 COL1A2, COL2A1, COL5A1, GRB2, HRAS, KRAS, MAP2K1, MAP2K2, PDGFA PTPN11, RAF1, SOS1,
STAT3, THBS4
REACTOME Signaling by insulin receptor 7.02E-05 EIF4E, EIF4EBP1, GRB2, HRAS, KRAS, MAP2K1, MAP2K2, RAF1, RPS6, RPS6KB1, SOS1
REACTOME Signaling by EGFR 0.0022 CDC42, GRB2, HRAS, KRAS, MAP2K1, MAP2K2, PTPN11, PXN, RAF1, SOS1




0.0035 ACTB, DES, IGF1, ITGB1, MYH7, MYL2, MYL3, TNNT2, TPM1, TPM3, TPM4, TTN
BIOCARTA Role of MAL in Rho-mediated
activation of SRF
0.044 ACTA1, CDC42, MAP2K1, MAP2K2, RAC1, RAF1, RHOA
BIOCARTA IGF-1 signaling 0.0067 FOS, GRB2, HRAS, IGF1, MAP2K1, PTPN11, RAF1, SOS1
PANTHER Integrin signaling 0.0070 BRAF, CDC42, COL1A2, COL2A1, COL5A1, FLNA, GRB2, HRAS, ILK, ITGB1, KRAS, MAP2K1,
MAP2K2, PXN, RAC1, RAF1, RHOA, RND2, RRAS, SOS1
KEGG Dilated cardiomyopathy 0.0099 ACTB, DES, IGF1, ITGB1, MYH7, MYL2, MYL3, TNNT2, TPM1, TPM3, TPM4, TTN
Network-predicted candidate genes
REACTOME Muscle contraction 2.71E-24 ACTN2, DMD, MYBPC1, MYBPC2, MYBPC3, MYH8, MYL1, MYL4, NEB, TCAP, TMOD1, TNNC1,
TNNC2, TNNI1, TNNI3, TNNT1, TPM2, VIM
KEGG Hypertrophic cardiomyopathy
(HCM)
9.68E-6 ACTC1, DMD, MYBPC3, TGFB1, TGFB2, TGFB3, TNNC1, TNNI3, TPM2,
PANTHER TGF-beta signaling pathway 1.07E-5 BMP2, LEFTY1, LEFTY2, LOC100271831, MAPK1, MAPK3, MSTN, NODAL, TGFB1, TGFB2, TGFB3
KEGG Dilated cardiomyopathy 2.35E-5 ACTC1, DMD, MYBPC3, TGFB1, TGFB2, TGFB3, TNNC1, TNNI3, TPM2
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112 candidate genes proposed by Barthold et al. (2008)
[7] from the overall candidate genes list (consisting of
179 unique human genes) and repeated the pathway
analysis. Nine genes from Barthold et al. (2008) [7] were
reported as CO candidate genes also in other studies,
therefore we retained them in the analysis, so that the
new list of candidate genes consisted of 79 genes. The
pathway analysis of these remaining 79 candidate genes
returned similar results as were obtained when using the
overall 179 candidate gene list. In fact, 10 of the 12
enriched pathways were the same after excluding the
discussed data from the candidate gene list. In particular,
the five pathways reported by Barthold et al. (2008) [7]
in rat (“cytoskeleton”, “muscle development”, “muscle
contraction”, “focal adhesion”, and “insulin signaling”)
were all confirmed in this independent validation ana-
lysis. The main effect of the gene removal were higher,
but still significant, p-values in the pathway analysis.
According to these results we can infer that inclusion of
the candidate genes from Barthold et al. (2008) [7] isnot the reason for the substantial overlap of the five
pathways identified in both studies. On the contrary, the
findings proposed here are a further confirmation of the
validity of the conclusions made by Barthold et al.
(2008) [7].
Surprisingly, when we searched the medical literature
for articles that describe pathologies where CO, cardio-
myopathy, and RAS signaling are common features, we
found a perfect matching with Noonan, Cardiofa-
ciocutaneous, LEOPARD, and Costello syndrome that all
belong to the class of RASopathies [79,80]. Features of
all four syndromes are different physical anomalies in-
cluding concomitant presence of cardiomyopathy due to
heart defects and, in males, cryptorchidism [79]. Noonan
syndrome (NS) is the most common single gene cause
of congenital heart disease, and NS subjects also present
other features as leukemia predisposition [81]. In par-
ticular, five different mutations in RAF1 were identified
in individuals with NS; four mutations causing changes
in the CR2 domain of RAF1 were associated with hyper-
trophic cardiomyopathy (HCM), whereas mutations in
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RAF1, and SOS1 mutants were identified as a major
cause of Noonan syndrome, BRAF of Cardiofa-
ciocutaneous, PTPN11 of LEOPARD, and HRAS of
Costello syndrome, providing new insights into RAS
regulation [80,81]. These genes have also been found to
be mutated in patients with RASopathies having crypt-
orchidism in a clinical picture. In NS patients having
CO in their clinical picture 11/14 had mutated PTPN11,
4/5 had mutated SOS1, and 1/2 had mutated RAF1.
BRAF has been found to be mutated in 2/3 patients with
Cardiofaciocutaneous syndrome having CO, PTPN11 in
1/4 patients with LEOPARD having CO, and HRAS in 2/
4 patients with Costello syndrome and CO [80,81].
However, the genes responsible for the remainder are
unknown, and the gene pathway relations responsible
for potential connections between unrelated features
such as cryptorchidism and HCM in RASopathies are
not clear. Therefore, we performed a network-based pre-
diction (see next paragraph) of CO candidate genes by
identifying the most significant first neighbors (in the
human protein-protein interaction network; PPIN) of
the 179 literature-collected candidates.
Pathway analysis of the network-predicted candidate genes
A new cohort of 43 candidate genes (Additional file 7:
Table S7) was predicted by PiNGO 1.11 [18], which is a
Cytoscape plug-in (see Methods) [19]. The question we
tried to address was which first-neighbor genes significantly
interact with the original cohort of 179 literature-collected
genes in the human PPIN. We adopted hypergeometric
statistical test and Bonferroni multiple testing correction.
The cohort of 43 network-predicted genes was strongly sig-
nificant (Bonferroni p-value < 0.0095); therefore, we con-
sider them as additional CO candidate genes.
In order to evaluate the importance of these new can-
didate genes we performed the pathway analysis (Table 3),
according to the same procedure already used in the pre-
vious paragraph (and described in the methods). The
most intriguing evidence is the presence of significant
pathways related to cardiomyopathy and muscle contrac-
tion in both sets of candidate genes (i.e. literature-
collected and network-predicted). Pathways common to
both sets of candidate genes represent a confirmation of
the validity and robustness of the results obtained in the
first pathway analysis and regarding the hypothesis of
connection between CO and cardiomyopathy, in NS. Yet,
it is also a quality proof of the procedure adopted for net-
work prediction of new candidate genes.
Pathway analysis of the overall CO candidate gene list (179
literature-collected and 43 network-predicted genes)
The first cohort of 179 literature-collected genes and the
second one containing 43 network-predicted genes werecondensed in a list of 222 unique genes - the overall
candidate gene list. We repeated the pathway analysis on
this list applying the same very stringent criteria used
above (Bonferroni multiple test correction and p-value
significant threshold of 0.01). The analysis suggested the
presence of 12 significant pathways associated with the
overall list of candidate genes in human (Table 4).
The “muscle contraction” pathway was the most signifi-
cant (in absolute) with Bonferroni corrected p-value of
4.55E-33 (Figure 3A); while the “hypertrophic cardiomy-
opathy” was the second most significant pathway with
Bonferroni corrected p-value of 1.21E-09 (Figure 3B).
These results are crucial for our study because they sug-
gest the presence of a strong genomic connection among
diverse pathways associated with clinical features that
seemed unrelated. To address relationship among these
mechanisms we created a matrix merging the information
related to the gene participation in several identified
pathways. Of the 222 (179 + 43) candidate genes, 172 were
filtered out because they were not present in at least two
of the 12 significant pathways. The resulting matrix
consists of 50 candidate genes in the rows and 12 enriched
pathways in the columns (Additional file 8: Table S8). The
matrix values are binary: 0 indicates that the gene is not
present in a pathway, whereas 1 indicates that the gene is
present.
Hierarchical bi-clustering of the matrix [83], both in
the rows and in the columns, was performed to detect
clusters of genes which participated in common
pathways, and clusters of pathways which share the
same genes, respectively. The result of this analysis is
provided in the Figure 4. The presence of two main
groups of clusters is evident. The first group is
constituted of “cardiomyopathy” (hypertrophic and
dilated), “muscle contraction” and “cardiac muscle con-
traction” pathways. The second group is constituted of
“focal adhesion”, “regulation of actin cytoskeleton, “in-
tegrin signaling”, “vascular smooth muscle contraction”,
“signaling by insulin receptor”, “signaling by PDGF”,
“RAS pathway”, and “TGF-beta signaling”.
In order to further investigate the relation between the
genes involved in the “cardiomyopathy” (hypertrophic
and dilated), the “muscle contraction” and the “RAS
pathway” and to interpret their role in creating
connections between the diverse pathway modules, we
searched the STRING database [20] for protein-protein
interactions, selecting only the interactions with high
confidence score. The outcome of this analysis is
represented in Figure 5. All the 50 genes presented at
least one interaction in the PPI network produced by the
STRING database. This network is provided as a supple-
mentary material (Additional file 9: Table S9).
The principal pathways involved in both, CO and
RASopathies, are displayed on the PPIN (Figure 5), and
Table 4 Pathway analysis of the overall candidate gene list (literature-collected and network-predicted)
Database Pathway Bonnferoni
p-value
Candidate genes involved in the pathway
REACTOME Muscle contraction 4.55E-33 ACTN2, DES, DMD, MYBPC1, MYBPC2, MYBPC3, MYH3, MYH8, MYL1, MYL2, MYL3, MYL4, NEB, TCAP,




1.21E-9 ACTB, ACTC1, DES, DMD,IGF1, ITGB1, MYBPC3, MYH7, MYL2, MYL3, TGFB1, TGFB2, TGFB3, TNNC1,
TNNI3, TNNT2, TPM1, TPM2, TPM3, TPM4, TTN
KEGG Dilated cardiomyopathy 1.21E-8 ACTB, ACTC1, DES, DMD, IGF1, ITGB1, MYBPC3, MYH7, MYL2, MYL3, TGFB1, TGFB2, TGFB3, TNNC1,
TNNI3, TNNT2, TPM1, TPM2, TPM3, TPM4, TTN
KEGG Focal adhesion 4.68E-7 ACTB, ACTN2, BRAF, CAV1, CCND1, CDC42, COL1A2, COL2A1, COL5A1, FLNA, GRB2, GSK3B, HRAS,
IGF1, IGF1R, ILK, ITGB1, MAP2K1, MAPK1, MAPK3, MYL2, MYL9, PDGFA, PPP1CA, PPP1CB, PRKCA,
PXN, RAC1, RAF1, RHOA, SOS1, THBS4
REACTOME Signaling by insulin
receptor
3.83E-6 EIF4E, EIF4EBP1, GRB2, HRAS, KRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, RAF1, RHEB, RPS6, RPS6KB1,
SOS1
KEGG Regulation of actin
cytoskeleton
4.29E-6 ACTB, ACTN2, BRAF, CDC42, CFL1, CHRM3, EZR, FGD1, FGF3, FGF9, FGFR1, FGFR2, HRAS, ITGB1,
KRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, MYL2, MYL9, PDGFA, PFN1, PPP1CA, PPP1CB, PXN, RAC1,
RAF1, RHOA, RRAS, SOS1
PANTHER TGF-beta signaling
pathway
7.01E-6 AMH, AMHR2, BMP2, BMP4, BMP5, BMP7, CDC42, FOS, FOXO1, FOXP3, HRAS, KRAS, LEFTY1, LEFTY2,
MAPK1, MAPK3, MSTN, NODAL, RHEB, RRAS, TGFB1, TGFB2, TGFB3
BIOCARTA Integrin signaling
pathway
1.35E-5 ACTA1, ACTN2, CAV1, GRB2, HRAS, ITGB1, MAP2K1, MAP2K2, MAPK1, MAPK3, PXN, RAF1, RHOA,
SOS1
REACTOME Signaling by PDGF 7.27E-5 COL2A1, COL1A2, COL5A1, GRB2, HRAS, KRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, PDGFA, PTPN11,
RAF1, SOS1, STAT3, THBS4
KEGG Cardiac muscle
contraction
0.0024 ACTC1, MYH7, MYL2, MYL3, TNNC1, TNNI3, TNNT2, TPM1, TPM2, TPM3, TPM4




0.0058 ACTA2, BRAF, MAP2K1, MAP2K2, MAPK1, MAPK3, MYH11, MYL9, PPP1CA, PPP1CB, PRKCA, PRKCE,
RAF1, RHOA
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This figure addresses the question of the relation be-
tween the common genetic mechanisms underlying CO
and RASopathies. Figure 5 provides a clear visualization
of the overlapping pathways and of the integrated net-
work of relations existing on proteomic level. At the best
of our knowledge, this is the first time that such relation
is presented, and it might help in understanding the re-
lation between co-presence of CO and cardiomyopathy
as clinical and apparently unrelated features in
RASopathies. This fact is clarified by the layout offered
in Figure 5 that reveals how the “cardiomyopathy” and
the “RAS signaling” pathways are connected by a pleth-
ora of interactions with high confidence score in the
STRING database. To investigate the precise type of
intra- and inter- pathway interactions we suggest to
mine the network that we provide in the supplementary
material (Additional file 9: Table S9). Figure 5 further
emphasizes how the “focal adhesion” and the “TGF-beta
signaling” pathways overlap the “cardiomyopathy”, the
“muscle contraction” and the “RAS signaling” pathways
by connecting proteins at different metabolic levels. The
relevance of the “focal adhesion” pathway, as well as the
importance of “cytoskeleton”, “muscle development”,
“muscle contraction”, and “insulin signaling” pathwaysin cryptorchidism were widely discussed [7]. However,
the referred study was conducted on a rat model and all
of the pathways were considered and treated separately.
Here, for the first time, we proceed to an integratomic
investigation of the genetic factors linked to CO in
human. Meanwhile, we offer the holistic perspective that
points out how clinical features apparently unrelated
with CO might be generated by genetic mutation(s)
which propagate at different pathway levels of the net-
work. This propagation on different pathway-modules
can justify the onset of multiple unrelated clinical
features in complex diseases, such as RASopathies.
The selection of 43 network-based predicted genes
considered together with these last disease-related
evidences are another proof that confirms the power of
PPIN for association of genes with diseases [21,84].
Our results are in concordance with previous
observations that alignment of human interactome with
human phenome enables identification of causative
genes (and networks) underlying disease families. Pheno-
typic overlap implies genetic overlap and human
phenome can be viewed as a landscape of interrelated
diseases, which reflects overlapping molecular causation
[6,85-88]. In addition, it has been already shown that
causative genes from syndromes that are phenotypically
AB
Figure 3 Pathways, containing literature-collected and network-predicted CO candidate genes. CO genes are marked with stars: red stars
stand for literature-collected genes, blue stars stand for network-predicted genes. Gene names are added in yellow boxes to the original pathway
images. A. Reactome pathway: Muscle contraction – human. B. KEGG pathway: Hypertrophic cardiomyopathy (HCM) – human.
Cannistraci et al. BMC Medical Genomics 2013, 6:5 Page 11 of 16
http://www.biomedcentral.com/1755-8794/6/5
Figure 4 Hierarchical bi-clustering of the CO candidate genes. Hierarchical bi-clustering of the matrix of the CO candidate genes present in
at least two pathways. The matrix consists of 50 candidate genes (rows) and 12 enriched pathways (columns). The black lines (full and dashed)
are used to indicate the modules corresponding to clusters of interacting proteins in the respective pathways.
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http://www.biomedcentral.com/1755-8794/6/5similar to a genetically uncharacterized syndrome can be
used to query the gene network for functionally related
candidate genes [89].
Candidate gene prioritization
Prioritization of candidate genes underlying complex traits
remains one of the main challenges in molecular biology
[11]. In this study we used three criteria for selecting the
most promising candidate genes: 1) number of independent
literature reports connecting the candidate gene with CO
(Table 2), 2) involvement of candidate genes in enriched
pathways (Table 3), and 3) position of candidate genes on
the genomic map (genes positioned in regions where
multiple CO associated data overlap were considered
positional candidates) (Figure 2).
Twenty genes have been suggested as a genetic cause
for CO in at least two independent studies (criterion 1)
using different study approaches (AMH, AMHR2, AR,
ARID5B, BMP7, EPHA4, ESR1, FGFR2, HOXA10, HRAS,
INSL3, LHCGR, MAP2K1, MSX1, NR5A1, RXFP2, SOS1,TNNI2, TNNT3, and WT1). Among them, INSL3 has
been associated with CO in eight, RXFP2 in five, and AR
in four independent studies. However, this approach
should be treated with some caution because of the pos-
sible bias towards research interest into more “popular”
genes. The approach will be more reliable after signifi-
cant amount of unbiased genome-wide studies is
available.
Considering involvement in enriched pathways (criter-
ion 2), the most promising candidates would be HRAS,
MAP2K1, MAP2K2, GRB2, RAF1 and SOS1, which are
all involved in seven or more enriched pathways. For the
literature-collected candidate genes involved in multiple
(four or more) CO-enriched pathways we assembled
genetic information relevant for further functional ana-
lyses: assignment to corresponding biological pathways,
genetic variability, and putative presence of polymorphic
microRNA (miRNA) target sites (Additional file 6: Table
S6). The importance of small non-coding RNAs
(ncRNAs) in gene regulation and pathogenesis of the
Figure 5 String protein-protein interaction network (PPIN) of the CO candidate genes. PPIN is obtained from the 50 CO candidate genes
interacting in the STRING database. The lines (full and dashed) delimit the presence of the diverse overlapped protein-pathway-modules. The
same line is used in the Figure 4 to indicate the modules corresponding to clusters of interacting proteins in the respective pathways.
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However, to our knowledge, there are no literature reports
associating ncRNAs or epigenetic factors with CO.
The most promising candidates meeting both
suggested criteria (1 and 2) are FGFR2 (reported in two
CO-associated studies/ involved in one CO-associated
pathway), HRAS (3/8), MAP2K1 (2/9), and SOS1 (2/5).
Additionally, TNNI2 and TNNT3 are reported in the li-
terature (once each), involved in one CO enriched path-
way (i.e. “muscle contraction”), and positioned in a
region overlapping chromosomal mutation.
Genomic regions involved in the chromosome
mutations on chromosomes 2, 4, 8, 9, 11, and X over-
lapped with 14 candidate genes suggested as positional
candidates (criterion 3): CAPG, MSX1, E2F5, PTCH1,
BICD2, RPS6, FGFR2, HRAS, PAX6, WT1, TNNI2,
TNN3, FLNA, and MECP2. Additionally, three network-
predicted candidate genes, FHL2, TMOD1 and MYBPC3overlapped with chromosomal mutations. Considering
suggested prioritization criteria, HRAS gene meets all of
them.
Reliability of such methodologically different approaches
is not always comparable (for example, data from
genome-wide expression experiments is much less
validated than syndromic or transgenic data); therefore,
ranking candidate genes based only on a number of differ-
ent reports/approaches is not always feasible. However,
less validated data may also be of high biological relevance
and should not be discarded for hypothesis-driven
approaches. To increase reliability of the collected hetero-
geneous data we tested in silico how candidate genes
interact at the proteomic level. Although integratomic
approaches are only partially established yet and have sev-
eral drawbacks, including already mentioned heterogen-
eity of input data, we believe that such approaches are a
reasonable and at the moment among the most promising
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experimentally validated in animal and/or human
populations. Similar integratomics approach was already
used for identification of candidate loci for mammary
gland associated phenotypes [8], male infertility [9], and
obesity [10,91], and could be adapted to any other com-
plex trait.Conclusions
In this study we present an overview of CO associated
candidate regions/genes and suggest pathways poten-
tially involved in the pathogenesis of the disease. The in-
tegrative, comparative-genomics approach, and in silico
analyses of the collected data aim to help solving the
problem of fragmented and often contradictory data
extracted from different methodologically focused stud-
ies. The protein-protein interactions analysis revealed
the most relevant pathways associated with CO candi-
date gene list and enabled us to suggest additional candi-
date genes based on network prediction. Described
systems biology approach will contribute to a better
understanding of genetic causes for cryptorchidism and
provides possible example how integration and linking
of complex traits related data can be used for hypothesis
generation. Publicly available online CO gene atlas and
data entry option will allow researcher to enter, browse,
and visualize CO associated data. The proposed
network-based approach elucidates co-presence of simi-
lar pathogenetic mechanisms underlying diverse clinical
syndromes/defects and could be of a great importance
in research in the field of molecular syndromology. This
approach has also a potential to be used for future devel-
opment of diagnostic, prognostic, and therapeutic
markers. The developed integratomics approach can be
extrapolated to study genetic background of any other
complex traits/diseases and to generate hypothesis for
downstream experimental validation.Additional files
Additional file 1: Table S1. Chromosomal abnormalities and CNVs
associated with cryptorchidism.
Additional file 2: Table S2. Selected clinical syndromes that feature CO
in their clinical picture.
Additional file 3: Table S3. Transgenic and knock-out murine models
that display cryptorchid phenotype.
Additional file 4: Table S4. Genes tested for association with CO.
Additional file 5: Table S5. Genes with expression patterns associated
with CO. Genes with expression patterns associated with CO in rat
(adapted from [7]) and genomic location of their human orthologs.
Additional file 6: Table S6. The literature collected candidate genes
involved in multiple (four or more) CO-associated pathways.
Additional file 7: Table S7. Forty-three network-predicted
CO-associated candidate genes.Additional file 8: Table S8. Protein network information matrix for
candidate genes. Protein network information matrix for candidate genes
involved in at least two pathways significant for literature-collected and
network-predicted candidate genes. The matrix consists of 50 rows (each
row corresponds to a different gene involved in at least two pathways)
and 12 columns (each column corresponds to a different pathway),
where 0 indicates that the gene is not present in a pathway and 1
indicates that the gene is present in it.
Additional file 9: Table S9. STRING network data: list of protein
network interactions present in STRING with high confidence score.
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